2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1392

Decreased Injection Site Pain Associated with New Etanercept Formulation in Patients with Rheumatoid Arthritis or Psoriatic Arthritis

Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

9:00AM-11:00AM: Abstract Number: 1447

Decreased Lymphatic Drainage in the Hands of Flaring RA Patients As Measured By Indocyanine Green Clearance Via Real Time Near Infrared Imaging

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1598

Depression and Anxiety Reduce Probability of Achieving a State of Minimal Disease Activity in Patients with Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1389

Depression and the Patient Reported Outcomes Measurement Information System in Systemic Lupus Erythematosus

Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

9:00AM-11:00AM: Abstract Number: 1660

Depression Has a Greater Impact on Psoriatic Arthritis Than Rheumatoid Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1510

Depression Is a Major Driver of Functional Capacity in Patients with Rheumatoid Arthritis Regardless of Disease Activity

Rheumatoid Arthritis – Diagnosis, Manifestions, and Outcomes Poster – ARHP

9:00AM-11:00AM: Abstract Number: 1738

Detect Outperforms Echocardiography Based Screening Guidelines for Early Detection of Systemic Sclerosis Associated Pulmonary Arterial Hypertension

Systemic Sclerosis and Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1370

Detection of an Autoantibody Profile to Characterize Patients with Early (Pre-symptomatic) Knee Osteoarthritis: Data from the Osteoarthritis Initiative

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1052

Detection of Precursors of RANK- Osteoclast-like Cells (Olcs) in Peripheral Blood and Olcs in Bone Tissue from Rheumatoid Arthritis Patients

Osteoarthritis and Joint Biology – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 1263

Develop a Master Algorithm for Drug Withdraw Strategy in Reduction of Adverse Events – a Machine Learning Model from the Smart System of Disease Management (SSDM)

Measures and Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 1037

Develop an in Vitro Model to Test the Different Behavior of mtDNA in OA and Healthy Patients, Based on Mitochondrial Activity and Metabolic Response

Osteoarthritis and Joint Biology – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 1261

Development a Core Domain Set to Assess Shared Decision Making Interventions in Rheumatology: An OMERACT White Paper to Facilitate Endorsement

Measures and Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 1394

Development and Pilot of a Patient Satisfaction Scale in Rheumatology

Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

9:00AM-11:00AM: Abstract Number: 1042

Development of a Neo-Epitope Specific Assay for Serological Assessment of Type X Collagen Degradation and Its Potential Diagnostic Value for Knee Osteoarthritis

Osteoarthritis and Joint Biology – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 1455

Development of a Predictive Model of Radiological Damage in Patients with Rheumatoid Arthritis Based on Artificial Intelligence

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].